Overview
My passion is for leveraging health care data and innovative technologies to advancing excellence and equity in health care. I dually-enrolled in both a Bachelor's and Master's program in public health at the University of Georgia studying epidemiology and then continued my training at Emory's school of medicine and UT Southwestern's internal medicine residency. Now, I am enrolled as a research fellow in Duke's division of pulmonary and critical care, where I have the opportunity to advance my research career as well as become an expert clinician in pulmonary medicine. I am proud to bring my passion for excellence and equity in care to both my research and my clinical practice.
Current Appointments & Affiliations
Adjunct Associate in the Department of Medicine
·
2023 - Present
Medicine, Pulmonary, Allergy, and Critical Care Medicine,
Medicine
Recent Publications
The Epidemiology of Combined Pulmonary Fibrosis and Emphysema (CPFE) Among Mid-Atlantic Veterans.
Journal Article Ann Am Thorac Soc · May 19, 2025 RATIONALE: Combined pulmonary fibrosis and emphysema (CPFE) is a unique phenotype with important prognosis and management implications in patients with idiopathic pulmonary fibrosis (CPFE-IPF) and other forms of fibrotic interstitial lung disease (CPFE-fIL ... Full text Link to item CiteRacial disparities in lung function by pulmonary function testing among lung transplant candidates and race-specific reference equations.
Journal Article JHLT Open · May 2025 Non-White patients with interstitial lung disease (ILD) experience racial disparities in lung transplant waitlist mortality. Race-specific equations for spirometry may contribute by underestimating restriction severity in non-White candidates. We analyzed ... Full text Link to item CitePolypharmacy and potentially inappropriate medication (PIM) use among older veterans with idiopathic pulmonary fibrosis (IPF) - a retrospective cohort study.
Journal Article BMC Pulm Med · April 21, 2025 BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a deadly respiratory disease of older patients. IPF therapies (antifibrotics) are efficacious in slowing disease progression, but they are critically underutilized. Potential barriers to antifibrotic use a ... Full text Link to item CiteEducation, Training & Certifications
Emory University, School of Medicine ·
2017
M.D.